Objective response rate (ORR) was 24% in 29 evaluable patients and increased in inflamed (PD-L1 positive) tumors, with ORR of 41% in patients with > 1% PD-L1 expression No significant added toxicity...

Data from the dose-ranging part of a Phase I/II trial of monalizumab in 18 patients with advanced gynecologic malignancies; Monalizumab had no dose-limiting toxicities, highest dose level chosen for...

Enrollment in the first-in-human trial of IPH4102 in relapsed/refractory cutaneaous T-cell lymphomas (CTCL) is proceeding with no dose-limiting toxicities to date; Dose level 9 out of 10 is currently...

Mondher Mahjoubi, MD, appointed Chairman of Innate Pharma’s Executive Board Hervé Brailly, PhD, co -founder and CEO from Company inception, appointed Chairman of Supervisory Board Governance changes...

Preliminary results from the dose-escalation part of Phase I study in patients with relapsed/refractory cutaneous T-cell lymphomas Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH)...

The combination of lirilumab and nivolumab in a phase I study of advanced solid tumors showed no added toxicity over nivolumab monotherapy; Data supports ongoing Phase I cohort expansion of lirilumab...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces that safety data for two Phase I studies of lirilumab in combination with nivolumab or ipilimumab conducted by...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announced that the Data and Safety Monitoring Board (“DSMB”) completed its seventh assessment of the EffiKIR study and...

Cash, cash equivalents and financial assets* for the Company amounted to €243.6m (million euros) as of June 30, 2016 Company is building foundations to become a commercial stage biopharmaceutical...

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), announces that it will host an event for analysts and investors in London to discuss the Company’s corporate strategy and ongoing...